The speediest device developer is Roche, but a look at companies’ strategies shows the perils of relying on bought-in tech.
The overall rate of device approvals in 2019 is holding steady on last year – but the types of approvals are different.
The recent disappointing sales of drug-coated devices for peripheral arterial disease look likely to become the norm.
An acquisitive company has a plan for the future.
The Cabana trial has finally reported, but the data are inconclusive.